Market Overview:
The global heparin sodium API market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of venous thromboembolism (VTE), rising geriatric population, and growing demand for low molecular weight heparins (LMWHs). However, the high cost of treatment and stringent regulatory requirements are restraining the growth of this market. Based on type, the global heparin sodium API market is segmented into unfractionated heparin and LMWHs. The LMWHs segment is expected to grow at a higher CAGR than the unfractionated heparin segment during the forecast period. This can be attributed to their better safety profile and lower risk of bleeding as compared with unfractionated heparins. Based on application, the global heparn sodium API market is divided into treatment of VTE, complications of pregnancy, cardioversion of atrial fibrillation/flutter, and other applications. The treatmentof VTE segment accounts for majority share in this market owingto its high prevalence worldwide.
Product Definition:
Heparin Sodium API is a drug used to prevent and treat blood clots. It works by increasing the activity of antithrombin III, which helps to prevent the formation of clots.
Unfractionated Heparin:
Unfractionated heparin, also known as basic heparin or without a coefficient, is an injectable form of anticoagulant medication used to prevent blood clotting. It's major application is in the treatment of thrombocytopenia (low platelet count) and pulmonary embolism (PE). Unfractionated Heparin sodium API has been approved by the U.S.
Low Molecular Heparin:
Low molecular heparin (LMH) is a form of anticoagulant drug used to prevent deep vein thrombosis and pulmonary embolism. LMH has a low potential for causing bleeding complications when compared to warfarin.
Application Insights:
The treatment of venous thromboembolism (VTE) segment dominated the global market in 2017. The increasing prevalence of VTE due to immobility and associated risk factors such as cancer, surgery, and trauma are contributing to its dominance over other applications. According to a study published by NCBI in 2018, VTE accounted for around 1% - 2% of all hospital admissions globally. In addition, according to the same source approximately 90-120 cases per million people are reported annually worldwide with about 25000 deaths due to VTEs globally. Thus rising incidences coupled with high awareness is driving the demand for heparin sodium API for the treatment of VTE which is expectedto grow at lucrative growth rate duringthe forecast period owingto its abilityto prevent complications associatedwith deep vein thrombosis (DVT) & pulmonary embolism (PE).
Regional Analysis:
Europe dominated the global market in terms of revenue share in 2017. The presence of favorable government policies and initiatives pertaining to VTE treatment, along with high healthcare expenditure levels, is expected to drive the regional market over the forecast period. Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising geriatric population and prevalence of CVDs & PEs that require anticoagulant therapy.
In terms of volume consumption North America was at par with Europe in 2017 due mainlyto higher incidence rates associated with CVDs & PEs which are majorly caused due lack of proper clotting factors among others.
Growth Factors:
- Increasing incidence of cardiovascular diseases (CVDs) across the globe is expected to drive the demand for heparin sodium API over the forecast period.
- Growing geriatric population is also anticipated to fuel market growth as this population is more susceptible to CVDs.
- Rising awareness about the benefits of using heparin sodium API in prevention and treatment of CVDs is projected to propel market growth during the forecast period.
- Technological advancements in drug delivery systems are likely to create new opportunities for heparin sodium API manufacturers over the next few years. 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Heparin Sodium API Market Research Report
By Type
Unfractionated Heparin, Low Molecular Heparin
By Application
Treatment of Venous Thromboembolism, Complications of Pregnancy, Cardioversion of Atrial Fibrillation/Flutter, Other
By Companies
Hepalink, Changshan Pharm, Qianhong Bio-pharma, Opocrin, Pfizer, Aspen Oss, King-friend Biochemical Pharmaceutical, Bioibérica, Dongcheng Biochemicals, Jiulong Biochemicals, Tiandong, Xinbai, Yino Pharma Limited, Deebio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
120
Number of Tables & Figures
84
Customization Available
Yes, the report can be customized as per your need.
Global Heparin Sodium API Market Report Segments:
The global Heparin Sodium API market is segmented on the basis of:
Types
Unfractionated Heparin, Low Molecular Heparin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Treatment of Venous Thromboembolism, Complications of Pregnancy, Cardioversion of Atrial Fibrillation/Flutter, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hepalink
- Changshan Pharm
- Qianhong Bio-pharma
- Opocrin
- Pfizer
- Aspen Oss
- King-friend Biochemical Pharmaceutical
- Bioibérica
- Dongcheng Biochemicals
- Jiulong Biochemicals
- Tiandong
- Xinbai
- Yino Pharma Limited
- Deebio
Highlights of The Heparin Sodium API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Unfractionated Heparin
- Low Molecular Heparin
- By Application:
- Treatment of Venous Thromboembolism
- Complications of Pregnancy
- Cardioversion of Atrial Fibrillation/Flutter
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Heparin Sodium API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Heparin Sodium API is a type of medication used to prevent and treat blood clots. It is also used to reduce the risk of stroke in people who have had a heart attack.
Some of the major players in the heparin sodium api market are Hepalink, Changshan Pharm, Qianhong Bio-pharma, Opocrin, Pfizer, Aspen Oss, King-friend Biochemical Pharmaceutical, Bioib©rica, Dongcheng Biochemicals, Jiulong Biochemicals, Tiandong, Xinbai, Yino Pharma Limited, Deebio.
The heparin sodium api market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Heparin Sodium API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Heparin Sodium API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Heparin Sodium API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Heparin Sodium API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Heparin Sodium API Market Size & Forecast, 2020-2028
4.5.1 Heparin Sodium API Market Size and Y-o-Y Growth
4.5.2 Heparin Sodium API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Unfractionated Heparin
5.2.2 Low Molecular Heparin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Treatment of Venous Thromboembolism
6.2.2 Complications of Pregnancy
6.2.3 Cardioversion of Atrial Fibrillation/Flutter
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Heparin Sodium API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Heparin Sodium API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Unfractionated Heparin
9.6.2 Low Molecular Heparin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Treatment of Venous Thromboembolism
9.10.2 Complications of Pregnancy
9.10.3 Cardioversion of Atrial Fibrillation/Flutter
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Unfractionated Heparin
10.6.2 Low Molecular Heparin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Treatment of Venous Thromboembolism
10.10.2 Complications of Pregnancy
10.10.3 Cardioversion of Atrial Fibrillation/Flutter
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Unfractionated Heparin
11.6.2 Low Molecular Heparin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Treatment of Venous Thromboembolism
11.10.2 Complications of Pregnancy
11.10.3 Cardioversion of Atrial Fibrillation/Flutter
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Unfractionated Heparin
12.6.2 Low Molecular Heparin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Treatment of Venous Thromboembolism
12.10.2 Complications of Pregnancy
12.10.3 Cardioversion of Atrial Fibrillation/Flutter
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Unfractionated Heparin
13.6.2 Low Molecular Heparin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Treatment of Venous Thromboembolism
13.10.2 Complications of Pregnancy
13.10.3 Cardioversion of Atrial Fibrillation/Flutter
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Heparin Sodium API Market: Competitive Dashboard
14.2 Global Heparin Sodium API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Hepalink
14.3.2 Changshan Pharm
14.3.3 Qianhong Bio-pharma
14.3.4 Opocrin
14.3.5 Pfizer
14.3.6 Aspen Oss
14.3.7 King-friend Biochemical Pharmaceutical
14.3.8 Bioibérica
14.3.9 Dongcheng Biochemicals
14.3.10 Jiulong Biochemicals
14.3.11 Tiandong
14.3.12 Xinbai
14.3.13 Yino Pharma Limited
14.3.14 Deebio
